Expertise in
20
conditions

Lugui G. Qiu

National Clinical Research Center For Hematological Disorders & State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Tianjin, CN 
Expertise in
20
conditions
National Clinical Research Center For Hematological Disorders & State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Tianjin, CN 
OverviewLocationsClinical Research

Overview

Lugui Qiu practices in Tianjin, China. Qiu is highly rated in 20 conditions, according to our data. Their top areas of expertise are Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Transplant.

Their clinical research consists of co-authoring 308 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

National Clinical Research Center For Hematological Disorders & State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, Tianjin, China
Other Locations
Jiuting, 201600, China
Beijing, China
Shanghai, 201615, China
Guangzhou, 510080, China
Hangzhou, China
Changsha, China
Nanchang, China
Jinan, China
Hengshui, China
Xinxiang, China
300020, China
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, 288 Nanjing Road, Xiaobailou, 300020, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I Study to Evaluate the Safety, Tolerability, PK/PD and Immunogenicity Characteristics of Recombinant Anti-CD38 and Anti-CD3 Bispecific Antibodies (Y150) for Injection in Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Study to Evaluate the Safety, Tolerability, PK/PD and Immunogenicity Characteristics of Recombinant Anti-CD38 and Anti-CD3 Bispecific Antibodies (Y150) for Injection in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Y150
Study Phase: Phase 1
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 26, 2022
Intervention Type: Biological
Study Drug: CD19 CAR T cells
Study Phase: Phase 1
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
A Single Cohort, Open-label, Multicenter, Dose-escalation Study of Safety and Efficacy of BZ019 for Adult CD19 Positive Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: March 17, 2020
Intervention Type: Biological
Study Drug: BZ019
Study Phase: Phase 1
View 5 Less Clinical Trials

308 Total Publications

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Qiu's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile